Eisai has another plant expansion in the works. After announcing plans in April to build a new plant in China, the Japanese drugmaker now says it will add a new packaging facility in the U.K.
Medtronic is debuting a new surgical tool in Europe designed to help surgeons perform osteotomies to treat severe spinal curvature in adults. The launch comes in tandem with a new CE mark.
Natera has signed a deal to get its non-invasive prenatal test distributed across Switzerland and Scandinavia, another advance for the young company as it touts Panorama to be the most reliable diagnostic in the now-crowded space.
Sanofi is gearing up for commercial production at an insulin plant in Russia which it bought in 2010 from a Polish company.
Contract manufacturing has become a hot investment, and Novartis thinks it may be time to cash in. The Swiss drugmaker and its partners are looking at selling their joint venture, LTS Lohmann.
Two drugmakers reported regulatory victories for therapies in the important European market. A European Medicines Agency committee endorsed approval of Celgene's ($CELG) pomalidomide for multiple myeloma and Aegerion's ($AEGR) Lojuxta for a genetic cause of high cholesterol called homozygous familial hypercholesterolemia.
U.K. technology giant Smiths Group is again mulling a multi-billion-dollar offer for Smiths Medical, reportedly weighing offers from CareFusion and others.
Sequenom has inked a deal with France's Laboratoire Cerba to expand the reach of the company's MaterniT21 Plus test, designed to non-invasively detect chromosomal abnormalities.
Teleflex picked up European approval to market its GPSCath device, designed to prop open vessels and reduce procedure times for vascular interventions.
Boston Scientific notched European approval for its Guide DBS system, a first-of-its-kind platform designed to help physicians target neuromodulation therapy.